Cargando…
SOX2 regulates paclitaxel resistance of A549 non-small cell lung cancer cells via promoting transcription of ClC-3
Paclitaxel (PTX) is widely used in the treatment of non-small cell lung cancer (NSCLC). However, acquired PTX drug resistance is a major obstacle to its therapeutic efficacy and the underlying mechanisms are still unclear. The present study revealed a novel role of the SRY-box transcription factor 2...
Autores principales: | Huang, Youwei, Wang, Xiangyu, Hu, Rendong, Pan, Guopeng, Lin, Xi |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
D.A. Spandidos
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9478990/ https://www.ncbi.nlm.nih.gov/pubmed/36069232 http://dx.doi.org/10.3892/or.2022.8396 |
Ejemplares similares
-
CLC-3 and SOX2 regulate the cell cycle in DU145 cells
por: Chen, Jiahong, et al.
Publicado: (2020) -
Cysteine Accessibility in ClC-0 Supports Conservation of the ClC Intracellular Vestibule
por: Engh, Anita M., et al.
Publicado: (2005) -
ClC chloride channels
por: Mindell, Joe, et al.
Publicado: (2001) -
Involvement of the Tubular ClC-Type Exchanger ClC-5 in Glomeruli of Human Proteinuric Nephropathies
por: Ceol, Monica, et al.
Publicado: (2012) -
Chloride Channelopathies of ClC-2
por: Bi, Miao Miao, et al.
Publicado: (2013)